RANI RANI THERAPEUTICS HLDGS INC

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

SAN JOSE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that three submitted abstracts were accepted for poster presentations at the 105th annual meeting of The Endocrine Society (ENDO 2023) taking place June 15-18, 2023, in Chicago, Illinois.

The first of Rani’s abstracts noted below will be featured in a news conference hosted by the Endocrine Society from 9-10 am C.T. on June 17, 2023 in Room W-186B in McCormick Place’s West Building.

Details of the abstracts being presented at ENDO are as follows:

Abstract Title:

Session Title: P69 - Bone and Mineral Metabolism: Hypoparathyroidism

Session Type: Poster Abstract

Date & Time: Saturday June 17, 2023, 1:00-2:00 pm C.T.

Location: McCormick Place, EXPO Hall

Presenter: Joshua Myers, MS

Nominated for Presidential Poster Competition: Endocrine Society to select winner

Selected for Rapid Fire Presentation: Quick preview poster presentation on a multimedia display to allow meeting attendees to further engage with the presenters at their paper poster. Rapid Fire presentations will take place in the Poster Pod area in the exhibit hall.

News Feature: This abstract will be featured in a news conference hosted by the Endocrine Society.

Abstract Title:

Session Title: P69 - Bone and Mineral Metabolism: Hypoparathyroidism

Session Type: Poster Abstract

Date & Time: Saturday June 17, 2023, 1:00-2:00 pm C.T.

Location: McCormick Place, EXPO Hall

Presenter: Kyle Horlen, DVM

Nominated for Presidential Poster Competition: Endocrine Society to select winner

Abstract Title:

Session Title: Session P44 - Reproductive Endocrinology: Female Reproduction – Clinical

Session Type: Poster Abstract

Date & Time: Friday, June 16, 2023, 12:00-1:00 pm C.T.

Location: McCormick Place, EXPO Hall

Presenter: Alyson Yamaguchi, DVM

Information about ENDO 2023 may be accessed at .

About Rani Therapeutics

Rani Therapeutics is a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit .

Investor Contact:

Media Contact:



EN
31/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RANI THERAPEUTICS HLDGS INC

 PRESS RELEASE

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to ...

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer. “We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase ...

 PRESS RELEASE

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the ...

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen - A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill® capsule versus subcutaneous injection -  SAN JOSE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the initiation o...

 PRESS RELEASE

Rani Therapeutics to Participate in the Evercore Healthcare Conference

Rani Therapeutics to Participate in the Evercore Healthcare Conference SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s management team will participate in the upcoming Evercore Healthcare Conference. Details below: 8th Annual Evercore Healthcare ConferenceDate: Wednesday, December 3, 2025 at 8:45 am E.T.Location: Coral Gables, FLPresenter: Chief Executive Officer, Talat Imran, ...

 PRESS RELEASE

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provid...

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update – Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Anomaly, Special Situations Funds, and Invus – – Appointed Abraham Bassan and Vasudev Bailey, Ph.D. to the Board of Directors – – Cash runway expected to extend into 2028 – SAN JOSE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings,...

 PRESS RELEASE

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Sema...

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025 SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule, the company’s oral delivery platform, at ObesityWeek® 2025 taking place both virtually and in-person on November 4-7, 2025 in Atlanta, Georgia. Details of the pre...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch